XML 84 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders' Equity
 12 Months Ended
Dec. 31, 2023
Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]  
Stockholders' Equity Stockholders' Equity
    The following information should be read in conjunction with the Consolidated Statement of Stockholders' Equity (Deficit).
    Common Stock Repurchases
On July 31, 2019, the Company announced that its Board of Directors approved the repurchase of up to $100.0 million of its common stock in open market purchases, including under Rule 10b5-1 and/or Rule 10b-18 plans. On November 4, 2021, the Company announced that its Board of Directors approved the repurchase of an additional $150.0 million of its common stock under this program. The stock repurchase program does not have an expiration date.
The Company did not repurchase any of its common stock in 2023. The Company repurchased 6,662,421 shares of its common stock for $60.0 million in 2022 and 4,658,544 shares of its common stock for $50.0 million in 2021, under the stock repurchase program. The amount and timing of repurchases are subject to a variety of factors including liquidity, stock price, applicable legal requirements, other business objectives and market conditions.
As of December 31, 2023, approximately $99.0 million remained available for stock repurchases under this authorization.
Dividends
    The Company paid quarterly dividends of $0.01 per share through the second quarter of 2023. On August 2, 2023, the Company’s Board of Directors elected to suspend the quarterly cash dividend of $0.01 per common share.
Accumulated other comprehensive loss
The balance in our AOCL is set forth in the following table:
 
December 31, 2023
December 31, 2022
 (Dollars in thousands)
Foreign currency translation adjustments, net of tax$(19,188)$(29,354)
Commodities, interest rate and foreign currency derivatives, net of tax7,730 21,284 
Total AOCL$(11,458)$(8,070)